New legislation in Congress would prohibit limiting what pharmacists can tell patients about the cheapest way to pay for their prescriptions; drug companies, researchers, and health officials are trying to develop an overdose-reversal treatment that is more successful than naloxone against synthetic opioids; a Texas lawsuit seeking to strike down the Affordable Care Act is being opposed by 16 Democratic attorneys general.
New legislation in Congress would prohibit insurers or pharmacy benefit managers from limiting what pharmacists can tell patients about the cheapest way to pay for their prescriptions. According to The Detroit News, some prescriptions may be cheaper for customers if they pay in cash, rather than their insurance co-pay, but pharmacists were unable to tell them that. The legislation is being sponsored by Senators Debbie Stabenow, D-Michigan, and Susan Collins, R-Maine. Research has shown customers overpay for prescriptions 23% of the time.
Naloxone is widely used to reverse opioid overdoses, but it has limited success against synthetic opioids. With the use of synthetic opioids on the rise, drug companies, researchers, and health officials are trying to develop a new treatment that may replace naloxone in certain cases, reported STAT. One option being pursued is tweaking buprenorphine, which is currently used to treat addiction, but may also be able to reverse an overdose with some changes.
A Texas lawsuit seeking to strike down the Affordable Care Act (ACA) has strong opposition from 16 Democratic attorneys general (AGs), led by California AG Xavier Becerra. As a result, there is a showdown between red and blue states with 19 Republican-led states joining Texas’ case, according to The New York Times. Texas’ lawsuit claims the repeal of the individual mandate as part of the Republican tax bill means that the ACA is no longer valid.
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
FDA Expands Access to Approved CAR T-Cell Therapies by Eliminating REMS
June 30th 2025The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and expand patient access.
Read More
Allergies and Asthma Prevalence Rise With Climate Change Extremes and Pollutants
June 30th 2025Increasing environmental events driven by climate change and human activity exacerbate allergy and asthma conditions, further compounded by exposure to persistent pollutants like per-and polyfluoroalkyl substances and microplastics.
Read More